Increased apoB/apoA-I ratio Is predictive of peripheral arterial disease in initially healthy 58-year-old men during 8.9 years of follow-up

Angiology

Volumn 60, Issue 5, 2009, Pages 539-545

  Johansson, L ^a   Schmidt, C ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Ankle " brachial index; Apolipoprotein A I; Apolipoprotein B; Peripheral arterial disease

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B;

ADULT; ANKLE BRACHIAL INDEX; ARTERY DISEASE; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; FEMORAL ARTERY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; SWEDEN;

AGED; ANKLE; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; BIOLOGICAL MARKERS; BLOOD PRESSURE; BRACHIAL ARTERY; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; PERIPHERAL VASCULAR DISEASES; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS; SWEDEN; TIME FACTORS; UP-REGULATION;

EID: 70350520174     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/0003319708324925     Document Type: Article

References (42)

1. American Heart Association. Heart Disease and Stroke Statistics-2004 Update. (1 st ed.) Dallas, TX: American Heart Association ; 2003: 20-22.
2. Schrdieder F., Dihem N., Kareem S., et al. A modified calculation of ankle-brachial index is far more sensitive in the detection of peripheral arterial disease. J Vasc Surg. 2006 ; 44: 531-536.
3. Pasternak RC, Criqui MH, Benjamin EJ, et al. Atherosclerotic Vascular Disease Conference: Writing Group I: epidemiology. Circulation. 2004 ; 109: 2605-2612.
4. Wallenfeldt K., Bokemark L., Wikstrand J., Hulthe J., Fagerberg B. Apolipoprotein B/apolipoprotein A-I in relation to the metabolic syndrome and change in carotid artery intima-media thickness during 3 years in middle-aged men. Stroke. 2004 ; 35: 2248-2252.
5. Walldius G., Jungner I. Is there a better marker of cardiovascular risk than LDL cholesterol? Apolipoproteins B and A-I-new risk factors and targets for therapy. Nutr, Metab Cardiovasc Dis. 2007 ; 17: 565-571.
6. Walldius G., Jungner I. Apolipoprotein B and Apolipoprotein A-I: risk indicators of coronary heart disease and targets of lipid-modifying therapy. J Int Med. 2004 ; 255: 188-205.
7. Walldius G., Jungner I., Holme I., Aastveit AH, Kolar W., Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet. 2001 ; 358: 2026-2033.
8. Jadhav UM, Kadam NN Apolipoproteins: correlation with carotid intimamedia thickness and coronary artery disease. J Assoc Physicians India. 2004 ; 52: 370-375.
9. Rasouli M., Kiasari AM, Mokhberi V. The ratio of apoB/ apoA-I and lipoprotein (a) are the best predictors of stable coronary artery disease. Clin Chem Lab Med. 2006 ; 44: 1015-1021.
10. Van der Steeg WA, Boekholdt SM, Stein EA, et al. Role of the Apolipoprotein B-Apolipoprotein A-I in cardiovascular risk assessment: a case-control analysis in EPIC-Norfolk. Ann Int Med. 2007 ; 146: 640-648.
11. Vaverkova H., Frohlich J., Jackuliakova D., Novonty D. Comparison of apolipoprotein B and plasma lipids as target for lipid lowering treatment. Clin Biochem. 2005 ; 38: 509-513.
12. Roeters Van Lennep JE, Werterveld T., Roeters Van Lennep HWO Apolipoprotein concentrations during treatment and recurrent coronary artery disease events. Arterioscler Thromb Vasc Biol. 2000 ; 20: 2408-2413.
13. Sniderman AD, Furberg CD, Keech A. Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. Lancet. 2003 ; 361: 777-780.
14. Wagner AM, Ordonez-Llanos J. Apolipoproteins and predictions of fatal myocardial infarction. Lancet. 2002 ; 359: 1863-1864.
15. Walldius G., Jungner I. The apo B/apo A-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy-a review of the evidence. J Intern Med. 2006 ; 259: 493-519.
16. Sniderman AD, Jungner I., Holme I., Aastveit A., Walldius G. Error that result from the TC/HDL C ratio rather than the apo B/apo A-I ratio to identify the lipoprotein-related risk of vascular disease. J Intern Med. 2006 ; 259: 455-461.
17. Lamarche B., Moorjani S., Lupien PJ, et al. Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Quebec Cardiovascular Study. Circulation. 1996 ; 94: 273-278. (Pubitemid 26266109)
18. Moss AJ, Goldstein RE, Marder VJ, et al. Thrombogenic factors and recurrent coronary events. Circulation. 1999; 99: 2517-2522.
19. Talmud PJ, Hawe E., Miller GJ, Humphries SE Nonfasting apolipoprotein B and triglyceride levels as a useful predictor of coronary heart disease events. Arterioscler Thromb Vasc Biol. 2002 ; 22: 1918-1923.
20. Schmidt C., Fagerberg B. ApoB/apoA-I ratio is related to femoral artery plaques in 64-year-old women, also in cases with low LDL cholesterol. Atherosclerosis. 2008 ; 196: 817-822.
21. Simes RJ, Marschner IC, Hunt D., et al. Relationship between lipids levels and clinical outcomes in the long-term intervention with pravastatin in ischemic disease (LIPID) trial. Circulation. 2002 ; 105: 1162-1169.
22. Powell JT, Edwards RJ, Worrell PC, Franks PJ, Greenhalgh RM, Poulter NR Risk factors associated with the development of peripheral arterial disease in smokers: a case-control study. Atherosclerosis. 1997 ; 129: 41-48.
23. Angquist KA, Johnson O., Ericsson M., Tollin C. Serum lipoproteins and apolipoproteins AI and AII in male patients with peripheral arterial insufficiency. Acta Chir Scand. 1982 ; 148: 675-678.
24. O'Neal DN, Lewicki J., Ansari MZ, Matthews PG, Best JD Lipids levels and peripheral vascular disease in diabetic and non-diabetic subjects. Atherosclerosis. 1998 ; 136: 1-8.
25. Bradby GV, Valente AJ, Walton KW Serum high density lipoproteins in peripheral vascular disease. Lancet. 1978 ; 8103: 1271-1274.
26. Pilger E., Pristautz H., Pfeiffer KH, Kostner G. Retrospective evaluation of risk factors for peripheral atherosclerosis by stepwise discriminant analysis. Atherosclerosis. 1983 ; 3: 57-63.
27. Suurk1/4la M., Fagerberg B., Wendelhag I., Agewall S., Wikstrand J. Atherosclerotic disease in the femoral artery in hypertensive patients at high cardiovascular risk. The value of ultrasonographic assessment of intima-media thickness and plaque occurrence. Risk Intervention Study (RIS) Group. Arterioscler Thromb Vasc Biol. 1996 ; 16: 971-977.
28. Bokemark L., Wikstrand J., Wedel H., Fagerberg B. Insulin, insulin properties and intima-media thickness in carotid artery in 58-year-old clinically healthy men. The atherosclerosis and insulin resistance study (AIR). Diabetic Med. 2002 ; 19: 144-151.
29. Schmidt C., Fagerberg B., Hulthe J. Non-stenotic ultrasound-assessed femoral artery plaques are predictive for future cardiovascular events in middle-aged men. Atherosclerosis. 2005 ; 18: 25-30.
30. Wallenfeldt K., Hulthe J., Bokemark L., Wikstrand J., Fagerberg B. Carotid and femoral atherosclerosis, cardiovascular risk factors and C-reactive protein in relation to smokeless tobacco use or smoking in 58-year-old men. J Intern Med. 2001 ; 250: 492-501.
31. Schmidt C., Fagerberg B., Wikstrand J., Hulthe J. ApoB/ apoA-I is related to femoral artery plaques and is predictive for future cardiovascular events in healthy men. Atherosclerosis. 2006 ; 189: 178-185.
32. Tivesten ...., Hulthe J., Wallenfeldt K., Wikstrand J., Ohlsson C., Fagerberg B. Circulating estradiol is an independent predictor of progression of carotid artery intima-media thickness in middle-aged men. Clin Endocrinol Metab. 2006 ; 91: 4433-4437.
33. Sniderman AD, Jungner I., Aasteit AH, Wallidius G. Errors that result from the TC/HDL C ratio rather than the apoB/apoA-I ratio to identify the lipoprotein-related risk of vascular disease. J Intern Med. 2006 ; 259: 455-461.
34. Walldius G., Jungner I., Aasteveit A., Holme I., Furberg CD, Sniderman AD The apoB/apoA-I ratio is better than cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk. Clin Chem Lab Med. 2004 ; 42: 1355-1363.
35. Schmidt C., Fagerberg B., Wikstrand J., Hulthe J. ApoB/ apoA-I is related to femoral artery plaques and is predictive for future cardiovascular events in healthy men. Atherosclerosis. 2005 ; 189: 178-185.
36. Cui R., Iso H., Yamagishi K., Tanigawa T., et al. Relationship of smoking and smoking cessation with ankle-to-arm blood pressure index in elderly Japanese men. Eur J Cardiovasc Prev Rehabil. 2006 ; 13: 243-248. (Pubitemid 44097730)
37. Newman AB, Siscovick DS, Manolio TA, et al. Ankle-arm index as a marker of atherosclerosis in the Cardiovascular Healthy Study. Circulation. 1993 ; 88: 837-845.
38. Meijer WT, Grobbee DE, Hunink MG, Hofman A., Hoes AW Determinants of peripheral arterial disease in the elderly: the Rotterdam study. Arch Intern Med. 2000 ; 160: 2934-2938. (Pubitemid 32009050)
39. Coppola G., Novo S. Statins and peripheral arterial disease: effects on claudication, disease progression and prevention of cardiovascular events. Arch Med Res. 2007 ; 38: 479-488.
40. Buchwald H., Varco RL, Boen JR, et al. Effective lipid modification by partial ileal bypass reduced long-term coronary heart disease mortality and morbidity: five-year posttrial follow-up report from the POSCH. Arch Intern Med. 1998 ; 158: 1253-1261.
41. Aung PP, Maxwell HG, Jepson RG, Price JF, Leng GC Lipid-lowering for peripheral arterial disease of the lower limb. Cochrane Database Syst Rev. 2007 ; 4: CD000123.
42. Rifai CJ, Bachorik PS, Albertt JJ Lipids, lipoproteins and apolipoproteins. In: Burits CA, Ashwood ER, eds. Tietz-Textbook of Clinical Chemistry. 3 rd ed. Philadelphia, PA: Saunders ; 1999 ; 809-861.